Colossal Biosciences in Talks to Raise New Funding at $20B–$30B Valuation
The de-extinction startup continues to expand its biotech innovations.
1Colossal's Growth Story
Colossal Biosciences reached a $10.2 billion valuation last year. Now, it is in talks to raise new funding at a $20–$30 billion valuation. This increase reflects investor confidence in the company's groundbreaking biotech innovations.
2Revenue Streams
Colossal has started generating revenue over the past year. The company has three main revenue sources: conservation technologies, spin-off startups, and biodiversity credits. Deals with countries like the U.S. and UAE have strengthened its financial position.
3Spin-offs and Collaborations
Colossal has launched three spin-offs: Breaking (plastic degradation), Form Bio ($30M funding), and Astromech ($2B valuation). It also partnered with the University of Tasmania to protect Tasmanian devils, expanding its biotech influence.
4De-Extinction Projects
Colossal aims to revive six species, with the bluebuck antelope as its latest target. It also plans to commercialize its artificial womb technology next year, which could have applications in human fertility treatments.
5Biodiversity Credits
The company plans to sell biodiversity credits by reintroducing extinct species to their habitats. These credits, similar to carbon credits, are part of Colossal's strategy to create a sustainable revenue model.
6Deep Tech Sector Trends
Colossal's success highlights the rise of deep tech sectors like longevity and alternative energy. Its innovative approach could set new standards in biotechnology and conservation.